Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 248-253

  Ricardi, Umberto ^a   Frezza, Giovanni ^b   Filippi, Andrea Riccardo ^a   Badellino, Serena ^a   Levis, Mario ^a   Navarria, Piera ^c   Salvi, Fabrizio ^b   Marcenaro, Michela ^d   Trovò, Marco ^e   Guarneri, Alessia ^a   Corvò, Renzo ^d   Scorsetti, Marta ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Early stage; Lung cancer; Non small cell lung cancer; Radiotherapy; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BRACHIAL PLEXUS NEUROPATHY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIB FRACTURE; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; TELANGIECTASIA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; ITALY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84901911154     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.015     Document Type: Article

References (24)

1. Senthi S., Lagerwaard F.J., Haasbeek C.J., Slotman B.J., Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012, 13(8):802-809.
2. Baumann P., Nyman J., Hoyer M., Wennberg B., Gagliardi G., Lax I., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
3. Fakiris A.J., McGarry R.C., Yiannoutsos C.T., Papiez L., Williams M., Henderson M.A., et al. Stereotactic body radiation therapy for early-stage non small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677-682.
4. Ricardi U., Filippi A.R., Guarneri A., Giglioli F.R., Ciammella P., Franco P., et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010, 68:72-77.
5. Koto M., Takai Y., Ogawa Y., Matsushita H., Takeda K., Takahashi C., et al. A phase II study on stereotactic body radiotherapy for stage I non small-cell lung cancer. Radiother Oncol 2007, 85:429-434.
6. Timmermann R., Paulus R., Galvin J., Michalski J., Straube W., Bradley J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
7. Andratschke N., Zimmermann E., Boehm E., Schill S., Schoeknecth C., Thamm R., et al. Stereotactic radiotherapy in histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol 2011, 101:245-249.
8. Matsuo Y., Shibuya K., Nagata Y., Takayam K., Norihisa Y., et al. Prognostic factors in stereotactic body radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1104-1111.
9. Verstegen N.E., Lagerwaard F.J., Haasbeck C.J., Slotman B.J., Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011, 101:250-254.
10. Pan H., Simpson D.R., Mell L.K., Mundt A.J., Lawson J.D. A survey on stereotactic body radiotherapy use in the United States. Cancer 2011, 117:4566-4572.
11. Ramella S., Maranzano E., Frata P., Mantovani C., Lazzari G., Menichelli C., et al. Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey. Tumori 2012, 98:66-78.
12. Palma D.A., Visser O., Lagerwaard F.J., Belderbos J., Slotman B.J., Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28(35):5153-5159.
13. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:694-705. IASLC International Staging Committee, Cancer Research and Biostatistics; Observers to the Committee, Participating Institutions.
14. Guckenberger M., Allgauer M., Appold S., Dieckmann K., Ernst I., Ganswindt U., et al. Safety and efficacy of stereotactic body radiotherapy for stage I non-small cell lung cancer in routine clinical practice: a pattern of care and outcome analysis. J Thorac Oncol 2013, 8(8):1050-1058.
15. Allibhai Z., Taremi M., Bezjack A., Brade A., Hope A.J., Sun A., et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013, 87(5):1064-1070.
16. Nair V.S., Krupitskaya Y., Gould M.K. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009, 4:1473-1479.
17. Nair V.J., MacRae R., Sirisegaram A., Pantarotto J.R. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys 2014, 88(2):314-318.
18. Soldà F., Lodge M., Ashley S., Withington A., Goldstraw P., Brada M. Stereotactic radiotherapy for the treatment of primary non-small cell lung cancer. Systematic review and comparison with a surgical cohort. Radiother Oncol 2013, 109(1):1-7.
19. Van Baardwijk A., Tomè W.A., Van Elmpt W., Bentzen S.M., Reymen B., Wanders R., et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012, 105(2):145-149.
20. Varlotto J., Fakiris A., Flickinger J., Medford-Davis L., Liss A., Shelkey J. Matched-pair propensity score comparisons of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer 2013, 119(15):2683-2691.
21. Lagerwaard F.J., Verstegen N., Haasbeek C.J., Slotman B.J., Paul M.A., Smit E.F., et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 83:348-353.
22. Lagerwaard F.J., Aaronson N.K., Gundy C.M., Haasbeeck C.J., Slotman B.J., Senan S. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 2012, 7:1148-1154.
23. Louie A.V., Rodrigues G., Hannouf M., Zaric G.S., Palma D.A., Cao G.Q., et al. Stereotactic body radiotherapy versus surgery for stage I NSCLC: a Markov model-based decision analysis. Int J Radiat Oncol Biol Phys 2011, 81(4):964-973.
24. Senan S. Surgery versus stereotactic radiotherapy for patients with early-stage non-small cell lung cancer: more data from observational studies and growing clinical equipoise. Cancer 2013, 119(15):2668-2670.